CQXA Holdings Pte. Ltd. forlænger tilbudsperioden til 2. marts 2026 i forhold til overtagelsestilbuddet til aktionærerne i Asetek

CQXA Holdings (a 100% subsidiary of China-based Chunqiu) has extended its recommended cash takeover offer for Asetek A/S to 2 March 2026, with the Danish Financial Supervisory Authority approving the second supplement on 13 February 2026. As of 12 February 2026 the bidder has received preliminary, non‑binding acceptances for 298,015,958 Asetek shares, representing approximately 93.65% of the company (ex‑treasury), but completion remains conditional on outstanding Chinese outbound investment approvals (MOFCOM, NDRC, SAFE); the bidder expects these to be resolved or waiting periods to expire allowing closing in Q1 2026.

Analysis

Market structure: The near-consummation of Chunqiu’s tender for Asetek (ASTK) concentrates OEM cooling IP and manufacturing under 603890.SS, benefiting Chunqiu via vertical integration and potential margin expansion (estimate +3–7ppt EBIT over 12–24 months from cost synergies). Minority ASTK holders who haven’t tendered will be cashed out at the offer price (preliminary 93.65% acceptances), reducing free float and raising illiquidity and control premium risks. Downstream rivals in PC cooling/ODM face higher competitive pressure on OEM contracts but limited immediate price shock to end-consumers.

Risk assessment: Primary tail risks are regulatory (MOFCOM/NDRC/SAFE rejection or onerous conditions) and geopolitical (export/technology controls) which could push ASTK equity down 15–40% if the deal collapses; probability non-trivial given ODI scrutiny. Timing windows: immediate (by Mar 2–3: preliminary update), short-term (Mar 6: final result; Mar 10–12: settlement), long-term (12–24 months for integration). Hidden dependencies include SAFE FX approvals for cross-border payment and any China-driven national security reviews impacting Taiwanese supply chains.

Trade implications: Merger-arbitrage on ASTK is the cleanest play: buy shares up to within 0.5–1.5% of the announced cash offer (size 1–3% NAV) and target capture between Mar 3–12. If spread persists or regulatory delay extends beyond Mar 20, buy deep-in-the-money puts at 1–2% notional to cap downside. Tactical long exposure to Chunqiu (603890.SS) of 1–2% NAV reflects upside from integration; hedge with short position in a China hardware/component ETF if domestic weakness appears.

Contrarian angles: Consensus assumes deal closes; market underprices a binary regulatory reversal or a modest topping bid (there’s ~6–12% chance of a price increase to secure 100% ownership), which would compress arb upside but lift ASTK holders. Historical Chinese ODI reviews have delayed deals 1–6 months; if approvals are delayed rather than denied, the arb is time-risky but intact — don’t overpay for immediacy. Unintended consequence: forced minority squeeze or protracted dual-listing disputes that create illiquidity and litigation exposure for remaining public holders.

Key Decisions for Investors

• Establish a merger-arbitrage long position in Asetek (ASTK) sized 1–3% of NAV if share price is trading ≥1% below the announced cash offer; plan to exit on settlement (expected Mar 10–12) or upon a buyout price increase above your entry+target spread.
• Buy put protection on ASTK (1–2% NAV equivalent) expiring May 2026 (to cover an extended regulatory delay) with strike ~10–15% below offer price to cap tail loss in case of ODI rejection.
• Initiate a selective long in Chunqiu (603890.SS) 1–2% NAV to capture integration upside, and hedge with a −0.5% NAV short position in a China hardware/components ETF (e.g., CSIIT or comparable) to isolate idiosyncratic M&A upside from sector risk.
• If ASTK spread narrows to <0.5% and liquidity is poor, avoid adding and instead monitor Mar 3 preliminary result; only tender (if eligible) if you require immediate liquidity or if final acceptance ≥98% is announced.
• If a competing bid or regulatory condition appears, be prepared to add to long ASTK up to 2% NAV on a confirmed topping bid (price rise ≥5%) and trim Chunqiu exposure correspondingly to keep net M&A-relative risk neutral.